Nystatin Oral Suspension 100,000 Units/mL: Patient Guide
What nystatin oral suspension is used for
Nystatin oral suspension is a liquid antifungal medicine used for candidiasis, commonly called oral thrush. The cited US prescription product is labeled for candidiasis in the oral cavity. It contains 100,000 USP nystatin units in each milliliter (mL).
The concentration describes how much nystatin is present in a given volume of liquid. It does not state how many milliliters a person should take for each dose. The prescribed dose volume depends on the product label, the patient, the infection being treated, and the country where the product is authorized.
Indications can also differ between products with the same concentration. The cited UK product is authorized for prevention and treatment of candidal infections involving the oral cavity, oesophagus, and intestinal tract, as well as specified newborn prophylaxis. Those broader uses should not be assumed to apply to the cited US product.
Use the formulation dispensed to you for the purpose stated on its label or prescription. Do not use nystatin oral suspension for unrelated human infections, and do not assume that uses described for other products or nonhuman medicines apply to your product.
How nystatin works-and what it cannot treat
Nystatin binds to sterols in the cell membranes of susceptible Candida organisms. This changes the membrane's permeability and damages the fungal cells. In an oral suspension, the medicine acts mainly where the liquid contacts the affected areas of the mouth.
Nystatin has insignificant gastrointestinal absorption, and most of a swallowed dose passes unchanged in the stool. Oral nystatin preparations must not be used to treat systemic fungal infections, which involve parts of the body beyond the local area treated by the suspension.
The medicine is directed at susceptible Candida infections. The cited US label reports no appreciable activity against bacteria, protozoa, or viruses. Oral nystatin suspension is not a treatment for bacterial or viral infections, even when those infections cause symptoms in the mouth.
A persistent coating, soreness, or other mouth symptom may have a cause that is not candidiasis, or may need further assessment if it does not improve. Do not assume that continuing the suspension will treat a different type of infection.
Nystatin oral suspension: US vs UK labeling
Dose instructions vary by product and country
The number 100,000 units/mL describes the concentration of the liquid, not the volume prescribed for a dose. Two products with that same concentration may have different authorized uses and different dose schedules. The US and UK labels cited for this guide illustrate this difference.
The cited US label lists 2 mL four times daily for infants and 4-6 mL four times daily for children and adults. It also describes limited clinical studies in which 1 mL four times daily was effective in premature and low-birth-weight infants. These are label-specific regimens, not instructions to select a dose without clinical guidance.
The cited UK label lists 1 mL four times daily for adult oral candidal infections and denture sores, and 1 mL four times daily for oral or intestinal candidosis in infants and children. It also lists 1 mL once daily for the product's specified newborn prophylaxis.
These schedules should not be combined or used interchangeably. Follow the prescription and patient information supplied with your exact product, together with the instructions from the prescriber or pharmacist. Do not choose a dose by converting the concentration into a volume yourself or by copying a schedule from another country.
How to measure and use the suspension correctly
Shake the suspension before measuring each dose so that the medicine is distributed through the liquid. Measure it with the supplied calibrated oral device rather than relying on an ordinary household spoon, whose volume may be inaccurate.
Place the suspension in contact with the affected oral areas for as long as possible before swallowing. The applicable label may give more specific instructions about how to distribute the liquid. For example, the cited US label directs that an infant's dose be placed as half the dose on each side of the mouth. It also directs avoiding feeding for 5-10 minutes in infants and young children; this detail should not automatically be applied to every formulation or age group.
The cited UK product advises against diluting the suspension because dilution may reduce its efficacy. Do not mix it with food, drinks, or additional liquid unless the product instructions or a healthcare professional specifically says to do so.
If the instructions on your bottle differ from general directions in this guide, use the bottle's instructions and ask a pharmacist to clarify any uncertainty. Product-specific directions take priority because formulations and approved administration instructions can differ.
Treatment duration and lack of improvement
Do not stop treatment solely because the mouth begins to look or feel better. The duration and endpoint stated on the product label should be followed, since the cited US and UK labels use different wording.
The cited US label directs continuing treatment for at least 48 hours after perioral symptoms disappear and cultures show eradication of Candida albicans. The cited UK label directs continuing treatment for at least 48 hours after symptoms disappear and advises reevaluation if symptoms worsen or persist beyond 14 days.
The 14-day reevaluation point belongs to that cited UK product and should not be treated as a universal maximum duration for every nystatin suspension. Do not assume that a symptom-free period alone establishes that treatment can be stopped when your product gives additional instructions.
Contact the prescriber or pharmacist if symptoms worsen, fail to improve as expected, return during or after treatment, or if you are unsure when the course should end. Persistent symptoms may require confirmation of the diagnosis or review of whether the exact product and instructions are appropriate.
Side effects and warning signs
Reported side effects include oral irritation or sensitization and gastrointestinal effects such as nausea, vomiting, diarrhea, and gastrointestinal upset. These effects can occur even though very little nystatin is absorbed from the gastrointestinal tract.
If irritation or sensitization develops, the cited labels direct discontinuation and medical advice. Possible hypersensitivity manifestations include a rash, hives (urticaria), swelling of the face or other tissues (angioedema), and bronchospasm. A person with known hypersensitivity to nystatin or any component of the formulation should not use that product.
Seek urgent medical assessment for facial or throat swelling, breathing difficulty, or signs of a severe allergic reaction. A severe or rapidly spreading skin reaction also requires urgent attention. Stevens-Johnson syndrome has been reported very rarely with nystatin products.
Mild gastrointestinal symptoms or local discomfort should still be discussed with a healthcare professional if they are troublesome, persistent, or worsening. Do not assume that every new symptom is harmless because the medicine acts mainly in the mouth and is minimally absorbed.
Contraindications, excipients, pregnancy, and interactions
Nystatin oral suspension is contraindicated in people with hypersensitivity to nystatin or to a component of the specific formulation. Check the ingredient list on the bottle, package leaflet, or official product information, especially if you have reacted to medicines or preservatives before.
Inactive ingredients differ between products. The cited US product includes sucrose, alcohol at no more than 1% by volume, dyes, parabens, propylene glycol, and flavorings. The cited UK product contains sucrose, ethanol, and parabens and warns against use in people with specified rare hereditary sugar-intolerance or malabsorption disorders. These ingredients should not be assumed to be present, or absent, in every nystatin suspension.
For pregnancy, the cited labels state that fetal harm is unknown and that use should be based on the expected benefit and potential risk. Animal reproductive studies were not conducted for these products. Discuss pregnancy or plans to become pregnant with a prescriber before using the suspension.
It is also unknown whether nystatin is excreted in human milk, and the cited labels advise caution during breastfeeding. The cited UK label reports no known medicinal interactions, but this is not a guarantee that every formulation is interaction-free for every person. Ask a pharmacist or prescriber to check the exact product and your complete medication list.
Storage, overdose, and when to seek professional help
Storage instructions are product-specific. The cited US product should be stored at 20-25°C (68-77°F), protected from light, and not frozen. The cited UK product should not be stored above 25°C. Follow the storage directions on the product dispensed to you rather than applying one country's instructions to another formulation.
If more than the prescribed amount is taken, contact a pharmacist, prescriber, poison service, or other appropriate urgent medical resource for advice. Oral nystatin doses above 5 million units daily have been associated with nausea and gastrointestinal upset, but this amount is not a recommended dose or a universally safe limit.
Seek professional help for a suspected overdose, severe or worsening side effects, facial swelling, breathing difficulty, a severe skin reaction, or irritation that develops after use. Contact the prescriber if the infection worsens or persists, or if the instructions on the bottle differ from those you were given.
When seeking advice, keep the bottle or package available. The exact concentration, ingredients, country-specific product information, prescribed volume, and storage instructions can all affect the guidance.
Nystatin oral suspension is an antifungal liquid preparation containing 100,000 USP nystatin units per milliliter, used for oral candidiasis (oral thrush). The stated concentration describes the amount of medicine in the liquid but does not indicate the volume to take per dose; prescribed dose volume depends on the product label, patient factors, and country-specific authorization. The US and UK products cited in this article illustrate that identical concentrations can have different approved uses and dosing schedules, so the exact product dispensed must be used according to its specific label or prescription.
The medicine acts locally by binding sterols in Candida cell membranes and should not be used for systemic fungal, bacterial, or viral infections. Proper administration involves shaking the suspension before each dose, measuring with the supplied calibrated oral device rather than a household spoon, and keeping the liquid in contact with affected oral areas before swallowing. Label-specific instructions on distribution, avoiding feeding after dosing, and avoiding dilution or mixing with food or drinks take priority over general guidance. Treatment should continue for the full duration stated on the product label, typically at least 48 hours after symptoms disappear and after eradication is confirmed, rather than stopping solely when symptoms improve. Possible side effects include oral irritation, nausea, vomiting, diarrhea, and gastrointestinal upset, as well as hypersensitivity reactions such as rash, hives, facial swelling, or breathing difficulty; use is contraindicated in those with known nystatin or formulation hypersensitivity. Pregnancy and breastfeeding require prescriber consultation due to unknown fetal harm and excretion in human milk. Storage is product-specific, and any overdose or severe/worsening symptoms warrant professional medical advice.
Publishing organization: NHS
Publishing organization: U.S. National Library of Medicine
Publishing organization: electronic Medicines Compendium
Publishing organization: electronic Medicines Compendium
Questions and comments
Please do not include passwords, medical record numbers, insurance information, financial information, precise addresses, or other confidential or directly identifying information in your message.